UK markets open in 6 hours 15 minutes

Omeros Corporation (OMER)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
14.78-0.20 (-1.34%)
At close: 4:00PM EDT
14.92 +0.14 (0.95%)
After hours: 05:47PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close14.98
Open15.07
Bid14.52 x 800
Ask15.59 x 1800
Day's range14.33 - 15.10
52-week range9.25 - 25.46
Volume570,140
Avg. volume516,470
Market cap921.214M
Beta (5Y monthly)1.13
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2021
    Business Wire

    Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2021

    SEATTLE, August 03, 2021--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2021, on Monday, August 9, 2021, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.

  • Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association
    Business Wire

    Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association

    SEATTLE, Jun 14, 2021--Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from its pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) were shared during an oral presentation at the virtual edition of the 26th Congress of the European Hematology Association (EHA). The presentation, entitled Narsoplimab (OMS721) Treatment Contributes to Improvements in Organ Function in Adult P

  • Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction
    Business Wire

    Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction

    Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced publication of the article "Selective inhibition of phosphodiesterase 7 enzymes reduces motivation for nicotine use through modu